Updated March 2016 – For more information on GcMAF, please join the GcMAF and GcMAF Cancer forums on Facebook – they are closed groups, so you have to wait for your membership to be confirmed. They contain up-to-date information on sources of GcMAF, and also feedback and contributions by people who are using GcMAF.
Updated 16 Mar 2014 re. vortex mixer
I’d previously written on GcMAF:
Supplement: GcMAF and Supplement: GcMAF yoghurt and my latest post, a talk given by Professor Ruggiero at the GcMAF clinic in February 2014.
Well, at the Fulda Integrative Cancer Conference 2013, I finally got to meet the famous Professor Ruggiero, who is the scientist behind the latest research on GcMAF.
(Professor Ruggiero is that rare beast, the research scientist who has also practiced as a radiologist, so he understands cancer in a way that very few pure research scientists do, having been at the coal face of cancer treatment.)
Prof. Ruggiero has a PhD in Molecular Biology and is also a certified Medical Doctor who has worked at Burroughs Wellcome Co North Carolina, USA publishing a seminal paper with Nobel Laureate Sir John Vane and, subsequently, at the National Cancer Institute of the NIH in Bethesda, USA.
Prof. Ruggiero specialised in Clinical Radiology. Consequently, his presentation at Fulda was peppered with slides of ultrasounds and visual proof of GcMAF’s effectiveness – in his own words: “I’m a clinical radiologist, and all radiologists love images!” (see this post on Professor Ruggiero and his skills with the ultrasound scan)
In his presentation, he showed that GcMAF has moved beyond its capability of activating macrophages and rebuilding the immune system. It is indispensable for the healthy function of vital systems, and is now being used by many clinicians to treat diverse pathologies like autism, CFS, ME and osteoarthritis.
So what did I learn about GcMAF that isn’t on the gcmaf.eu website?
No longer snake oil
There has been a sense that GcMAF is too good to be true – it’s not an exogenous drug that fixes some problem with side-effects, but works with the immune system to activate the body’s natural healing systems.
However, GcMAF is no longer the snake oil it was once considered to be. There’s a huge body of scientific research now backing its efficacy. There are 58,000 papers published on immunotherapies. For the past 20 years, macrophages and GcMAF have become a stronghold.
There’s a way of measuring the level of impact of research using Article Level Metrics, and of the 1.5 million articles across all scientific journals published, a GcMAF article on breast cancer in the August edition of the journal, Nutrients, is in the top 5% of articles tracked by Article Level Metrics. (A Novel Role for a Major Component of the Vitamin D Axis: Vitamin D Binding Protein-Derived Macrophage Activating Factor Induces Human Breast Cancer Cell Apoptosis through Stimulation of Macrophages)
How do we define GcMAF?
Is it a hormone? Is it a cytokine? Or is it a nutrient?
GcMAF is part of our body and created every time a newborn is being fed, or a wound is licked, or a mother kisses her baby. It is not a drug that fixes a problem. It is a natural component of our body. It is essential for the development and function of brain immuno-system and anti-cancer immno-surveillance.
GcMAF in cancer – new research – the incredible shrinking tumours – use in ascites
A trial was done by Japanese scientists (including the Atomic Bomb Institute of Nagasaki – one of the most famous cancer institutions in the world) on SCID mice (mice that tolerate transplantation of human hepatic carcinoma cells) – they transplanted human tumours into the mice. For one group, the control, they injected saline, and for the other group they injected GcMAF subQ, for 3 weeks. There was shrinkage in the tumours in this latter group.
(2010 Vitamin D Binding Protein-Macrophage Activating Factor Inhibits HCC in SCID Mice (PDF)
K Nonaka, S Onizuka, H Ishibashi, Y Uto, H Hori, T Nakayama, N Matsuura, T Kanematsu, H Fujioka.)
Prof. Ruggiero showed slides of ultrasounds he had personally taken of human patients with different types of cancer:
- In an example of human breast cancer with a tumour measuring 1.79cm, two weeks’ of treatment later the tumour measured 1.36cm. (The GcMAF was injected in an area close to the tumour).
- A case of Stage 4 breast cancer plus metastases in bones and lungs – reduction of 1.69cm to 1.29cm in primary tumour in two weeks, the tumour which was pointing towards the pectoral muscle (i.e. infiltration) – 6.9cm to 5.8 cm = 43% reduction in volume.
- A case of pancreatic cancer with diffused peritoneal carcinosis and ascites – two weeks’ later, the tumour is too diffused to be measured, with a significant reduction in ascitic fluid.
- A case of liver metastasis of kidney carcinoma: After 1 year of GcMAF plus ketogenic diet, a 12 cm mass was still there, but the patient was still alive, and the mass was scar tissue (confirmed by MRI a year before and a year after).
Why is GcMAF so powerful against cancer? GcMAF stimulates macrophages which kill cancer cells, it also directly inhibits cancer-cell proliferation and reverts the neoplastic phenotype. It also inhibits cancer cell-induced angiogenesis.
Current version of GcMAF is more potent, current protocol uses higher dosages
A practitioner in the audience stated that he had tried GcMAF two years ago on patients with late stage cancer with no results. That was my experience. I was injecting GcMAF subQ weekly, and then twice weekly with 100ng (0.25ml) per dose with no shrinkage in the tumour but my nagalase did decrease.
Ruggiero explained that the product is under constant development, and the original dosing and frequency for GcMAF proposed by Yamamoto in 2007-2008 (100ng twice a week) was possibly too low. Or the product by Yamamoto was different. Nowadays, they give the injectable form in doses of 400-800ng/daily or every 2 days. Best results are injecting around the tumour, or intravenously.
We also have to take into account that there will always be patients who do not respond to certain therapies.
Treating new illnesses
The Vitamin D receptor interacts with a number of genes which is why GcMAF is able to regulate a number of actions, e.g. neuro-protective effects.
Research into autism and effects of GcMAF and nagalase on autistic children – 14 weeks’ of treatment: 15% no responders, varying percentages of slight-improvement, moderate, considerable and 15% very-considerable improvement (using Clinical Impression of Global Improvement Scores). Nobody wants to use the word cure, but for the latter 15% the response has been so amazing, it is literally a cure.
GcMAF has been shown to established connections between neurons in vitro: undifferentiated neuron cells in a culture, when treated with GcMAF become differentiated, and there is a change in their morphology and establishment of connectivity between the neurons. These changes have been measured using trans-cranial sonography (to be published in Neuroscience).
In the brain, we have glial cells, and micro-glial activation takes place as a result of trauma or insult (e.g. brain injury). These cells do not have any extrusions and are unable to connect, and this produces neuro-toxic molecules that kills the neurons. This is also the basic pathogenic pathway for neuro-degenerative diseases which are activated by amyloid plaques. When in culture, GcMAF was added to these micro-glial cells and the cells turn from activated to normal ramified, glial cells and try to connect to each other.
Amyloid cells are prevalent in the development and rewiring of the brain. In vitro, GcMAF induces the differentiation toward the amyloid phenotype, and rebuilding the human brain might have something towards building the human mind.
This has implications for any neuro-degenerative disorders, including Parkinson’s and Alzheimer’s.
Professor Ruggiero demonstrated the effects of intra-peritoneal GcMAF on neuropathy in chemically-induced osteoarthritis in a rat. It was not an analgesic effect, but a neuro-protective effect.
New methods of administering GcMAF
When I used GcMAF two years ago I was told to inject it sub-cutaneously (into the belly) or intra-muscularly, into the forearm. The new protocol is to inject GcMAF either close to the tumour, or in the case of bone metastases, into the lymph nodes draining the site. Or even better, GcMAF should be administered intravenously. (Too late for me now!) For nerve damage, GcMAF should be injected as close as possible to the site of the damage, without actually impinging on the nerve.
Update 28 Feb 2014: Please do not inject GcMAF into tumours directly, even with the help of a physician as this might seed the cancer. There is also a new way of absorbing goleic, via a nebuliser – details are on the GcMAF.eu website: http://www.gcmaf.eu/treatment-centre/.
Update 16 Mar 2014: Before you fill the syringe, make sure you shake the vial of GcMAF/goleic to mix the contents. This is especially important if the goleic was frozen. Better still if you can mix the contents using a vortex mixer.
GcMAF yoghurt – how Maf314 is absorbed
GcMAF is also available in the form of a yoghurt, Maf314. We are programmed to eat and drink our nutrients and not absorb them intravenously. I had assumed that Maf314 was absorbed by the intestines and then into the bloodstream, but it turns out that Maf314’s action starts much earlier: Maf314 activates the mucosa-associated lymphoid tissue (MALT) in the gastrointestinal tract and also the tonsillar ring (this is the first line of defense in our immune system). Macrophages are activated in this area, go into the bloodstream as monocytes.
Maf314 can be produced using any mammalian milk (even goat and human) but not vegetable milk (i.e. not soya milk).
Interestingly, there was a case study of an autistic boy who had multiple allergies, including to milk, who was able to tolerate Maf314.
A new variant on GcMAF is Goleic, which is GcMAF compounded with oleic acid which apparently makes it more effective because it is bound to its own delivery system in the body, the Vitamin D Binding Protein or VDBP. Goleic can be injected or taken sublingually.
Oleic acid is found in olive oil. Needless to say, you cannot inject oleic acid as that would cause an embolism. Oleic acid by itself has the ability to kill cancer cells if conjugated with big proteins (such as albumin or Gc Protein). You can’t just drink olive oil for oleic acid and inject GcMAF. In order for oleic acid to work with GcMAF, the oleic acid-GcMAF molecule has to be manufactured in a lab to mimic what the physiologic assembly of GcMAF in our body. Vitamin D is already there in our bodies, so we don’t have to manufacture it, but with oleic acid, it has to be artificially-stuck to the 88 amino acids of the GcMAF molecule.
Adequate levels of Vitamin D needed for GcMAF to work
What are adequate levels of Vitamin D? According to Professor Ruggiero, nobody knows. The original recommended daily allowances was based on preventing rickets. He gives his patients 10,000 IU daily and makes sure that the patients drink sufficient amounts of fluid to prevent Vitamin D accumulation and toxicity.
Heparin/Warfarin inhibit action of GcMAF
Heparin and Warfarin (including Clexane) inhibits the action of GcMAF. I didn’t find out why this was the case. It did make me think twice before using Clexane which I usually do before a plane journey. I didn’t this time because it was a relatively short 1-hour journey.
Update 28 Feb 2014: I have been informed that Heparin has less of an effect on the more potent form of GcMAF – Goleic.
Not everyone responds – nagalase test
There was some debate about responsiveness, and yes, there are tests for GcMAF sensitivity by using the nagalase test. However, Prof Ruggiero pointed out that the test often took up to a month to process, and he often saw results within a week, so he didn’t rely on the nagalase test when proof was staring him in the face in the form of tumours that shrank visibly within weeks.
Please note: The opinions expressed in this talk are academic considerations only and they are not intended to represent medical advice to anyone. If you need medical advice, please refer to your healthcare professional.